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Abstract
Aims: Circulating microparticles (MPs) from metabolic syndrome patients
and those generated from apoptotic T-cells induce endothelial
dysfunction; however, the molecular and cellular mechanism(s) underlying
in the effects of MPs remain to be elucidated. Results: Here, we show that
both types of MPs increased expression of endoplasmic reticulum (ER)
stress markers XBP-1, p-eIF2alpha and CHOP and nuclear translocation of
ATF6 on human aortic endothelial cells. MPs decreased in vitro nitric
oxide release by human aortic endothelial cells, whereas in vivo MP
injection into mice impaired the endothelium-dependent relaxation
induced by acetylcholine. These effects were prevented when ER stress
was inhibited suggesting that ER stress is implicated in the endothelial
effects induced by MPs. MPs affected mitochondrial function and evoked
sequential increase of cytosolic and mitochondrial reactive oxygen
species (ROS). Pharmacological inhibition of ER stress and silencing of
neutral sphingomyelinase with siRNA abrogated all MP-mediated effects.
Neutralization of Fas-Ligand carried by MPs abolished effects induced by
both MP types, whereas neutralization of low density lipoprotein-receptor
on endothelial cells prevented T-lymphocyte MP-mediated effects.
Innovation and Conclusion: Collectively, endothelial dysfunction triggered
by MPs involves temporal cross-talk between ER and mitochondria with
respect to spatial regulation of ROS via the neutral sphingomyelinase and
interaction of MPs with Fas and/or low density lipoprotein-receptor. These
results provide a novel molecular insight into the manner MPs mediate
vascular dysfunction and allow identification of potential therapeutic




Metabolic syndrome defines a cluster of interrelated risk factors for
cardiovascular disease and diabetes. These factors include metabolic
abnormalities such as hyperglycemia, elevated triglyceride levels, low
high-density lipoprotein cholesterol levels, high blood pressure and
obesity, mainly central adiposity. Endothelial dysfunction participates
actively in the development of cardiovascular diseases associated with
metabolic syndrome (17). Among biological markers of endothelium injury,
microparticles (MPs) have been involved in the pathogenesis and
maintenance of cardiovascular, metabolic, and inflammatory diseases (9).
Indeed, these small vesicles, released from plasma membrane of
activated or apoptotic cells, carry proteins, nucleic acids and lipids that
can modify phenotype and function when delivered to target cells (21). In
particular, we have previously described that MPs from both apoptotic T
cells and from metabolic syndrome patients induced endothelial
dysfunction characterized by a decrease of nitric oxide (NO.) release
associated with the inhibition of endothelial NO-synthase (eNOS), and an
increase in oxidative and nitrative stresses in human endothelial cells (2,
25). In addition, when MPs from either apoptotic T cells or metabolic
syndrome patients were injected into mice, an impairment of
endothelium-dependent vasorelaxation in response to acetylcholine was
observed illustrating their pathophysiological relevance (2, 25). However,
the molecular and cellular mechanism(s) underlying in the effects of MPs
remain to be elucidated.
Several reports have shown that the activation of endoplasmic reticulum
(ER) stress response plays an important role in the pathogenesis of
metabolic disorders such as insulin resistance, type 2 diabetes and
obesity in animals (3, 26) as well as in humans (5). ER stress is induced by
the accumulation of misfolded proteins in the ER lumen which leads to the
activation of unfolded protein response (UPR). UPR is initiated by three
main ER transmembrane stress sensors: pancreatic endoplasmic
reticulum kinase (PERK), inositol-requiring enzyme 1 alpha (IRE1α), and
activating transcription factor 6 (ATF6) (7). The UPR is initially activated as
a pro-survival mechanism, however, prolonged UPR activation in
conditions such as obesity and metabolic syndrome leads to apoptosis,
oxidative stress, and inflammation and is referred to as the “ER stress
response”. Recently, Galán et al (10) have demonstrated that chemical
induction of ER stress with tunicamycin is associated with endothelial
dysfunction and increased oxidative stress in the arterial wall. Under
pathophysiological conditions such as hypertension, ER stress was
reported to be involved in endothelial dysfunction induced by angiotensin
II infusion (12). Furthermore, several lines of evidence strongly support
the link between mitochondrial dysfunction and cardiovascular
complications associated with metabolic syndrome. In the skeletal muscle
of type 2 diabetic patients, a downregulation of PGC1 alpha-responsive
genes involved in oxidative phosphorylation has been described (24).
Also, both basal and maximal ADP-stimulated respirations were
decreased in type 2 patients (22, 28). Similar results have been observed
in human cardiac muscle (23). Moreover, an important increase in ER-
mitochondria contact sites via the mitochondria-associated membranes
(MAMs) have been described during high-fat diet-induced obesity leading
to significant increase in hepatic lipid accumulation and decreased
mitochondrial oxidative function (3). In parallel, elevated reactive oxygen
species (ROS) production in cytosol, through the overexpression of the
NADPH isoform NOX4, and in mitochondria have beendetected in smooth
muscle aortic cells from atherosclerotic aged donors leading to impaired
mitochondrial function (32).
The aim of the present study is to decipher how MPs transfer their
message to induce endothelial dysfunction. Detailed analyses of the
mechanisms involved with special interest in the cross-talk between ER
and mitochondria in the regulation of oxidative stress were conducted.
This would help underpinning new molecular and cellular pathways
governing the vascular effects of MPs and will pave the way for identifying
novel potential targets against MP-induced endothelial dysfunction, which
predisposes to the initial pro-atherosclerotic events transforming
metabolic syndrome to different vascular diseases.
 
Results
T lymphocytic MPs induce endothelial dysfunction through ER stress
response activation
In response to treatment by MPs from apoptotic lymphocytes, UPR
pathway activation was assessed using the ER stress inhibitor
tauroursodeoxycholic acid (TUDCA), a chemical chaperone known to
enhance adaptive response of ER. MPs activated the three canonical
pathways associated with ER stress response: PERK, IRE1α and ATF6.
Indeed, MPs resulted in an increased phosphorylation of PERK and eIF2α,
as well as mRNA (not shown) and protein CHOP expressions (Fig. 1A-C).
In addition, MP treatment enhanced X-box binding protein 1 (XBP1)
splicing downstream to IRE1α (Fig. 1D) and induced the nuclear
translocation of ATF6 (Fig. 1E). Importantly, all these MP-evoked effects
were prevented in the presence of the ER stress inhibitor TUDCA (Fig 1A-
E). It should be noted that the ER stress inducer tunicamycin was able to
activate the same three classical ER stress pathways, which were partially
prevented by TUDCA (Fig. S1). Altogether, these data indicate that MPs
from apoptotic lymphocytes lead to the activation of all three arms of ER
stress response.
In order to verify whether ER stress response activation accounts for the
endothelial dysfunction induced by T lymphocyte MPs (25), in vitro NO.
production was evaluated in the absence or the presence of TUDCA. As
previously described, T lymphocyte MPs significantly decreased
NO.production in human aortic endothelial cells (HAoECs) (Fig. 1F).
Interestingly, the inhibition of ER stress with TUDCA abolished the ability
of MPs to reduce NO. production. In order to establish the
pathophysiological relevance of MPs, endothelium-dependent relaxation
in response to acetylcholine was evaluated following MP incubation with
mouse aortic rings in the absence or in the presence of TUDCA. MPs
significantly reduced the maximal acetylcholine-evoked relaxation, which
was improved by TUDCA (Fig. 1G). Finally, similarly to MPs, tunicamycin
was able to reduce both in vitro NO. release by endothelial cells and
acetylcholine-induced relaxation of mouse aortic rings. These effects
were partially prevented in the presence of TUDCA (Fig. S1).
Collectively, these results indicate that the activation of ER stress
response is implicated in endothelial dysfunction induced by T
lymphocyte MPs.
Involvement of membrane receptors in T lymphocyte MP-induced ER
stress in endothelial cells
We have previously shown that T lymphocyte MPs, through their Fas-
Ligand (FasL), induce vascular smooth muscle cell inflammation by
directly interacting with Fas of the recipient cells (31). Also, Yang et al (33)
have reported the involvement of low density lipoprotein receptor (LDL-R)
in the effects induced by T lymphocyte MPs on human retinal endothelial
cells. In order to determine the mechanism(s) by which MPs would induce
ER stress in HAoECs, the implication of both Fas/FasL interaction and
LDL-R was analyzed on MP-induced eIF2α phosphorylation. Interestingly,
we observed that neutralizing either FasL on MPs or LDL-R on endothelial
cells significantly reduced the MP-induced phospho-eIF2α (Fig. 2A).
Altogether, these data indicate that both Fas/FasL interaction and LDL-R
pathway are involved in MP-mediated ER stress induction.
Neutral sphingomyelinase (SMase) is the link between MP-activated
receptor and ER stress response induction
Since SMase cascade has been implicated in the regulation of ER stress
response (15), we assessed the involvement of SMase on MP-induced
effects. MP treatment induced an increase of neutral SMase expression,
which was prevented after neutralizing FasL on MPs (Fig. 2B) or when
LDL-R on endothelial cells was blocked (Fig. 2C). Treatment of endothelial
cells by MPs for 24 hours, but not for 4 hours, increased phospho-eIF2α.
Interestingly, silencing neutral SMase with a specific siRNA abolished MP-
induced increase of eIF2α phosphorylation after 24 hours of MP treatment
(Fig. 2D and 2E).
Moreover, using either the specific neutral SMase inhibitor GW4869 or
siRNA against neutral SMasecompletely prevented the MP-induced
reduction of eNOS activity as reflected by phospho-Ser eNOS/phospho-
Thr eNOS ratio (Fig. 2F and 2G). Furthermore, MP-induced NO. reduction
was abolished when neutral SMase was inhibited with GW4869 or
silenced by siRNA (Fig 2H). Altogether, these results suggest that neutral
SMase pathway controls the effects of MPs via Fas/FasL and LDL-R
interaction upstream of ER stress, eNOS activation and NO. production.
Cytosolic ROS production is upstream of T lymphocyte MP-induced ER
stress in endothelial cells
The possible involvement of oxidative stress in T lymphocyte MP-induced
ER stress activation was then assessed by incubating HAoECs with
various inhibitors the sources of ROS prior to MP stimulation. Indeed,
intracellular enzymatic systems with the capacity to generate ROS were
inhibited by allopurinol, apocynin, rotenone, or Nω-nitro-L-arginine (L-NA)
which are inhibitors of xanthine oxidase, NADPH oxidase, respiratory
chain complex I, and NOS, respectively. At 24 hours of treatment, none of
the ROS inhibitors modified the phosphorylation of eIF2α in the absence
of MPs (Fig. 3A). By contrast, all the inhibitors significantly decreased
eIF2α phosphorylation induced by MP treatment. These results suggest
that MP-induced ROS production from different sources is required for
the activation of ER stress response (Fig. 3B).
In order to establish the implication of cytoplasmic and mitochondrial ROS
in the effects of MPs, time course (i.e., 2, 4, and 24 hours) changes of
ROS levels were measured. Analysis of ROS levels, using electronic
paramagnetic resonance (EPR) and dihydroetidium (DHE) labeling,
showed that T lymphocyte MPs had no effect on ROS production at 2
hours, increased at 4 hours and returned to basal levels at 24 hours (Fig 3
C-I). This effect of T lymphocyte MPs on ROS production was not
affected by TUDCA. It is important to note that tunicamycin treatment
induced similar patterns of ROS production as those obtained with MPs
(Fig. S2). Interestingly, except for the mitochondrial ROS scavenger (mito-
TEMPO), all of the ROS inhibitors tested (allopurinol, apocynin, rotenone
and L-NA), reduced the early increase of cytosolic ROS production (Fig.
3J). To further analyze the enzyme involved in this ROS production, we
found that lymphocyte MPs increased the expression of p47phox
expression, a regulatory subunit of NAPDH oxidase at 4 hours, but not at
24 hours of treatment (Fig. 3K). This increase was partially prevented
after silencing of neutral SMase (Fig. 3K).
Altogether, lymphocyte MPs activate neutral SMase and induce an early
increase of cytosolic ROS production, upstream of ER stress activation via
at least the NADPH oxidase activation.
Cross-talk between ER and mitochondria is involved in the effects
induced by lymphocyte MPs in endothelial cells
To monitor mitochondrial ROS production, MitoSox probe was used.
Quantification of confocal images showed that mitochondrial ROS
fluorescence was reduced at 2 and 4 hours, but was greatly enhanced
after 24 hours of lymphocyte MP treatment (Fig. 4A-D). Interestingly, the
ER stress inhibitor TUDCA did not modify the reduction of MitoSox
fluorescence at 2 and 4 hours but completely abolished the increase at 24
hours. These results suggest that lymphocyte MPs induce a late increase
of mitochondrial ROS by a mechanism downstream of ER stress
activation. In order to confirm this, the mitochondrial ROS scavenger
mito-Tempo was used and did not show any effect on the increase of
phospho-eIF2α induced by lymphocyte MPs (Fig. 4E).
The effects of MPs on mitochondrial O2 consumption were then analyzed
in order to decipher the role of mitochondria on the MP-induced
endothelial dysfunction. Basal O2 consumption was not modified either by
MPs or MPs + TUDCA (Fig. 4F). However, MP treatment significantly
reduced both oligomycin and FCCP mitochondrial respirations which were
abolished when ER stress was inhibited with TUDCA (Fig. 4G and 4H).
These findings suggest that MPs are able to modify mitochondrial
respiration by a mechanism implicating ER stress. Exposure to MPs
resulted in an increase of complex IV activity (Fig. 4I) but had no effect on
the activity of the other complexes of the electron transport chain (not
shown). To confirm the interaction between ER and mitochondria through
the formation of tight physical junctions, MAM integrity wase analyzed
following MP treatment. As shown in Figure 4J and 4K, MPs induced MAM
disruption characterized by an overexpression of mitofusin 2 (Mfn2) and a
decreased expression of voltage-dependent anion channel 1 (VDAC1).
Moreover, these effects were prevented in the presence of the ER stress
inhibitor TUDCA suggesting that MP-induced ER stress leads to MAM
disruption on endothelial cells. Finally, to verify whether the MP effects on
mitochondria lead to endothelial dysfunction, NO. production was
measured in the presence of mito-Tempo. Scavenging mitochondrial ROS
with mito-Tempo abolished the decrease in NO. release induced by MPs
(Fig. 4L). This result suggests that alteration of mitochondrial function
with respect to respiration and ROS production, as a consequence of ER
stress, leads to endothelial dysfunction.
MPs from metabolic syndrome patients induce endothelial dysfunction via
Fas/FasL pathway and neutral SMase activation leading to ER stress
activation in vitro and ex vivo
We have previously described that MPs from metabolic syndrome
patients, but not those of non-metabolic syndrome subjects, induced
endothelial dysfunction (2). Here, we tested whether molecular pathways
involved in the effects of MPs from metabolic syndrome required also the
cross-talk between ER and mitochondria and oxidative stress similarly to
lymphocyte MPs. Therefore, MPs from metabolic syndrome patients or
non-metabolic syndrome subjects were isolated for whom detailed clinical
information is described in Supplementary Table 1. As expected,
metabolic syndrome patients showed greater visceral obesity as given by
waist circumference, enhanced triglyceridemia, and increased blood
pressure.
The total number of circulating MPs was significantly increased in patients
with metabolic syndrome compared to non-metabolic syndrome subjects
(Supplementary Table 2). Phenotypical characterization of cellular origin
of MPs showed an increase of ~6-fold (annexin V+), ~3.3-fold (CD41+),
and ~9.6-fold (CD146+)of the circulating level of procoagulant-, platelet-,
and endothelial-derived MPs in metabolic syndrome patients compared to
non-metabolic syndrome subjects, respectively. Also, levels of
erythrocyte- and leukocyte-derived MPs (CD235a+, CD45+) were
elevated (~9 and ~2.7-fold, respectively) in these patients.
As shown in Fig. 5A and 5B, MPs from metabolic syndrome patients, but
not from non-metabolic syndrome individuals, induced an increase in
phosphorylation of eIF2α and nuclear translocation of ATF6, which were
prevented in the presence of TUDCA. Similarly and as expected, MPs
from metabolic patients, in comparison to non-metabolic syndrome
subjects, caused a reduction in NO. release from endothelial cells, which
was abolished when ER stress was inhibited by TUDCA (Fig. 5C).
Moreover, incubation of mouse aortic rings with MPs from metabolic
syndrome patients, but not from non-metabolic syndrome subjects, was
associated to a reduced endothelium-dependent relaxation in response to
acetylcholine (Fig. 5D). This effect was prevented when vessels were
incubated in the presence of TUDCA. Taken together, these results
indicate that ER stress plays a key role in the induction of endothelial
dysfunction induced by MPs from metabolic syndrome patients.
In order to establish the receptor involved in the effects of MPs from
metabolic syndrome patients on endothelial cells, we neutralized either
FasL on MPs or LDL-R on HAoECs. Interestingly, neutralization of FasL but
not LDL-R on HAoECs, prevented the phosphorylation of eIF2α by
metabolic syndrome MPs (Fig. 5E) and abolished their ability to enhance
the expression of SMase (Fig. 5F). Finally, it is important to note that
silencing neutral SMase with siRNA significantly abolished the increase of
eIF2α phosphorylation by metabolic syndrome MPs both at early (4 hours)
and late stage (24 hours) of treatment (Fig. 5G and 5H), in contrast to T
lymphocyte MPs which were able to increase eIF2α at 24 hours only (Fig.
2E).
Cytosolic and mitochondrial ROS productions are downstream of
metabolic syndrome MP-induced ER stress in endothelial cells
As illustrated in Figure 6A-H, MPs from metabolic syndrome induced an
oxidative stress by increasing both cytosolic and mitochondrial ROS. DHE
staining showed that MPs from metabolic syndrome patients, in
comparison to non-metabolic syndrome subjects, enhanced cytosolic
ROS at 2 and 4 hours, but not at 24 hours (Fig. 6A-D). Also, MPs from
metabolic syndrome patients but not those from non-metabolic syndrome
subjects increased MitoSox fluorescence at 24 hours, but not at 2 or 4
hours of treatment of HAoECs (Fig. 6E-H). Cytosolic ROS, but not
mitochondrial ROS production, was abolished in the presence of ER stress
inhibitor TUDCA. Interestingly, MPs induced p47phox expression at 4
hours, but not at 24 hours, which was abolished after SMase silencing
(Fig. 7A and 7B). These results suggest that MPs from metabolic
syndrome patients activate neutral SMase and induce a spatio-temporal
increase of cytosolic ROS at early stage via the NADPH oxidase that
concur to ER stress and mitochondrial ROS at late stages of stimulation.




In the present study, we provide evidence to support the crucial role of ER
and mitochondria interaction in the deleterious effects of human MPs on
endothelial function. Most in detail, MPs from apoptotic T cells act on Fas
and LDL-R, then, via neutral SMase cascade induce cytosolic ROS
production which activates ER stress. Through the interaction between ER
and mitochondria, mitochondrial ROS are increased and contribute to
decreased bioavailability of NO. and the subsequent impairment of
endothelium-dependent vasorelaxation. Concerning MPs from metabolic
syndrome patients, Fas/FasL, but not LDL-R, participates in the response
induced by MPs. In addition, neutral SMase activation induces directly ER
stress which, in turn, increases both cytosolic and mitochondrial ROS. All
of these events lead to reduction of NO. release and the subsequent
impairment of endothelium-dependent vasorelaxation.
MPs have been described as cargo to delivery biological information
between cells. We have previously described that MPs from either
apoptotic T cells or metabolic syndrome patients induce endothelial
dysfunction through the inhibition of eNOS (2, 25). In the present study,
we show that both types of MPs induce endothelial dysfunction by ER
stress activation. Thus, in a similar manner to tunicamycin, MPs activate
the three canonical UPR pathways as illustrated by the increased
phosphorylation of PERK and eIF2alpha, XBP1 splicing and nuclear ATF6
translocation. ER stress activation has been described in endothelial cells
of obese patients (11) and after an intralipid infusion in endothelial cells
from healthy subjects (30), suggesting that metabolic disorders can lead
to ER stress that may be relevant to vascular diseases. In the present
study, the involved mechanisms in the ER induction of MPs from T cells
and those from metabolic syndrome patients were found to be slightly
different, probably due to the differences between MP origins. Indeed, we
show that metabolic syndrome patients display elevated levels of platelet-
and non-platelet-derived MPs, mainly from leukocytes, erythrocytes and
endothelial cells. In this respect, we have previously shown that the
effects of metabolic syndrome MPs on endothelial cells are probably
supported by non-platelet-derived MPs since this subset of MPs reduce
NO. production (2). In addition, Chironi et al (6) have found that circulating
levels of leukocyte-derived MPs were higher in metabolic syndrome
patients than in healthy individuals and that these levels positively
correlate with the number of metabolic syndrome components.
MPs carry proteins, lipids and nucleic acids, mainly mRNA and miRNA.
Since RNAse treatment has no effect in MP-induced responses on
HAoECs (not shown), we decided to analyze the direct interaction
between MPs and target cells via the ligand-receptor binding. We have
previously shown that interaction of FasL carried by MPs with Fas at the
surface of target cells mediates the induction of pro-inflammatory
proteins in the vascular wall (1, 31), whereas Yang et al(33) demonstrated
the involvement of LDL-R in the MP-induced effects. Here, we show that
both mechanisms participate to the effects of MPs from T cells, but only
Fas/FasL interaction is involved in the effects generated by MPs from
metabolic syndrome patients. Indeed, neutralization of LDL-R on
endothelial cells does not affect metabolic syndrome MP-induced ER
stress. Nevertheless, both types of MPs are able to activate neutral
SMase which has been directly related to endothelial dysfunction (for
review see 27). In addition, we provide proof that inhibition of neutral
SMase, or silencing its expression, strongly blocks MP-induced ER stress
and improves both eNOS activity and NO. production, illustrating the
implication of neutral SMase pathway on MP-induced endothelial
dysfunction.
Nonetheless, intracellular pathways involved in the effects of both types
of MPs show differential spatial and temporal regulation with respect to
cytosolic and mitochondrial pools of ROS. Activation of ER stress by MPs
from T cells is dependent on ROS production from different origins since
inhibitors of NADPH oxidase, xanthine oxidase, and mitochondrial
complex I prevented phosphorylation of eIF2α, which suggests a link
between the different ROS sources. Thus, it has been proposed that
NADPH oxidase plays a central role in orchestrating the activation and
dysfunction of other enzymes generating ROS (for review see 14). In
addition, the early increase (at 4 hours of treatment) on cytosolic ROS
production evoked by MPs from apoptotic T cells was not inhibited by
TUDCA, indicating that the enhancement of cytosolic ROS is upstream to
ER stress. Interestingly, silencing SMase partially prevented the increase
of p47phox subunit of NADPH oxidase induced by MPs at 4 hours
suggesting that SMase activation precedes NADPH oxidase-dependent
deleterious effects of MPs in endothelial cells. The SMase-p47phox-ROS
cascade has been described in vascular smooth muscle cells under
hypoxia conditions (8) and in neurons exposed to TNF-alpha (4), however,
to the best of our knowledge, the relationship of this cascade with ER
stress has never been studied. Furthermore, several studies showed that
cellular toxics such as arsenic or ischemia/reperfusion injury exert their
cytotoxicity by inducing apoptosis through a ROS-induced ER stress
which is associated to a mitochondrial dysfunction (29, 34). In the present
study, we provide evidence that mitochondrial ROS increase, changes on
mitochondrial respiration and complex IV activity are detected at late (24
hours) but not early (4 hours) MP treatment, and are abolished when ER
stress is inhibited, indicating that ER stress activation is mandatory for the
generation of mitochondrial ROS and perturbation of mitochondrial
function. Remarkably, scavenging of mitochondrial ROS by mito-Tempo
restores NO. production, illustrating the involvement of mitochondrial ROS
on the MP-induced endothelial dysfunction. Moreover, the enhanced
MAM alteration, which suggests an interaction between ER stress and
mitochondria, could account for the subsequent modifications of the
mitochondrial function. It is worth noting that ER and mitochondrial cross-
talk has been described in neurodegenerative (13) and metabolic
disorders (3, 18) suggesting that rescuing mitochondrial and ER stress
impairments may identify new targets against these pathologies.
In this respect, activation of SMase pathway by MPs from metabolic
syndrome patients directly induces ER stress which on its turn evokes an
increase of both cytosolic and mitochondrial ROS. It is important to note
that the spatio-temporal regulations of ROS induced by MPs from
metabolic syndrome patients are different from those of T lymphocytic
MPs. In fact, with respect to the increase of cytosolic ROS, ER stress
activation is downstream for the former and upstream for the latter. This
differential response probably results from the fact that a mixture of MP
subsets triggers the effects of metabolic syndrome MPs although we
previously reported that non-platelet MPs are responsible for endothelial
dysfunction. Indeed, it is well known that the content of MPs depends on
the cells they originate from, the stimulus of production and the
mechanism of vesicle generation (9).
The difference in the mechanism involved in ER stress response induced
by T lymphocytic MPs and those from metabolic syndrome patients might
explain the different level of endothelial dysfunction induced by both
types of MPs. We have no evidence of any NOS uncoupling nor
diminished levels of tetrahydrobiopterin in the present study, but it is most
likely that reduced acetylcholine-induced relaxation is due to spatio-
temporal increase of oxidative stress that leads to reduced NO
production. However, we cannot exclude that mechanisms other than NO
pathway, such as cyclo-oxygenase pathways, might be involved.
Nevertheless, the present study emphasizes the importance of ER stress
as a key control of oxidative stress leading to endothelial dysfunction by
both types of MPs. In this respect, it has been described that the
presence of unfolded proteins in the ER lumen is sufficient to activate
oxidative stress (for review see 19). This process may be related with the
fact that ER stress induction by MPs from metabolic syndrome patients
takes place early, only after 4 hours of MP treatment.
Collectively, we demonstrate that endothelial dysfunction triggered by
MPs involves temporal cross-talk between ER and mitochondria with
respect to spatial regulation of oxidative stress via the SMase route
(Figure 8). These events occur via interaction of MPs on endothelial cells
with Fas and/or LDL-R. These results highlight novel potential targets to
fight against the pivotal role of MPs on endothelial dysfunction leading to
the increase of cardiovascular complications including those associated
with metabolic syndrome.
Innovation
In last years, an increasing interest on circulating microparticles,
extracellular vesicules released from plasma membrane of cells, as
players in the development and maintenance of cardiovascular diseases
has been reported. Our study identifies a new pathway involving a spatio-
temporal cross-talk between endoplasmic reticulum and mitochondria in
the generation of oxidative stress accounting for the impairment of
endothelial function induced by microparticles from metabolic syndrome
patients and allow identification of potential therapeutic targets to treat
vascular complications associated with metabolic diseases.
 
Materials and Methods
MP production from T-cells. The human lymphoid CEM T-cell line was
used for MP production. Cells were seeded at 106 cells/ml and cultured in
serum-free X-VIVO 15 medium (Lonza, Basel, Switzerland). MPs were
produced as previously described (20, 25). Briefly, cells were treated with
actinomycin D (1 µg/ml; Sigma-Aldrich, St Quentin-Fallavier, France) for
24 hours. The supernatant was obtained by centrifugation at 750g for 15
minutes, and then at 1,500g for 5 minutes to remove cells and large
debris, respectively. MPs from the supernatant were washed after three
centrifugation steps (45 minutes, 14,000g) and recovered in 400 µl of
sterile NaCl 0.9%. Last washing medium was used as vehicle. The
determination of the amount of MPs was conducted by measuring MP-
associated proteins using the DC Protein Assay (Bio-Rad, Hercules, CA).
MPs were used at 10 µg/ml corresponding to 1,330 ± 312x103 MPs. This
concentration of lymphocyte MPs is found in plasma from patients
undergoing carotid endarterectomy (0-2x106 MPs/ml plasma) (16).
Metabolic syndrome patients. This study was approved by the ethics
committee of the University Hospital of Angers (France) (NCT: 00997165).
A total of 30 patients were included with metabolic syndrome from the
METABOL cohort at the Department of Endocrinology and Nutrition of the
University Hospital of Angers. Patients were eligible for inclusion,
according to the National Cholesterol Education Program-Adult Treatment
Panel III, when they had at least three of the following five criteria : i) waist
circumference >102 or 88 cm for men and women, respectively; ii)
systolic and diastolic pressures ³130/85 mmHg; iii) fasting glycemia ³1.1
g/l; iv) triglycerides ³1.5 g/l; and v) high-density cholesterol lipoprotein
<0.4 g/l in men or <0.5 g/l in women (Supplementary Table 1). Patients
with a history of cardiovascular diseases,preexistent chronic inflammatory
disease, and cancer were excluded. Normal controls consisted of 20
subjects who met less than two of the metabolic syndrome criteria (70%
without any component of metabolic syndrome).
MP collection from patients. Peripheral blood (20 ml) from non-metabolic
syndrome or metabolic syndrome subjects was collected in EDTA tubes
(Vacutainers; Becton Dickinson, Le Pont de Claix, France) from a
peripheral vein using a 21-gauge needle to minimize platelet activation
and was processed within 2 hours. After a 20-minute centrifugation at
270g, platelet-rich plasma was separated from whole blood which was
then centrifuged for 20 minutes at 1500g to obtain platelet-free plasma
(PFP). Two hundred µl of PFP were frozen and stored at -80°C until
subsequent use for MP characterization by flow cytometry. Remaining
PFP was subjected to three series of centrifugations each at 21,000g for
45 minutes to pellet MPs for in vitro studies, and the supernatant was
replaced by 200 µl of sterile 0.9% NaCl and stored at 4°C until
subsequent use. MPs from non-metabolic syndrome or metabolic
syndrome subjects were used at the circulating concentration detected
for each individual, as previously described (1, 2).
Characterization of MP phenotype. Membrane MP sub-populations were
discriminated in PFP according to the expression of membrane-specific
antigens (1, 2). Irrelevant human IgG was used as an isotype-matched
negative control for each sample. For numeration studies, 10 µl of PFP
were incubated with 5 µl of specific antibody (Beckman Coulter, Villepinte,
France). Annexin V binding was used to numerate phosphatidylserine-
expressing circulating MPs (2 µl of annexin V/5 µl PFP). After 30 minutes
at room temperature, samples were diluted in 300 µl of sterile 0.9% NaCl
or annexin-V labeling buffer, respectively. Then, an equal volume of
sample and Flowcount beads were added and samples were analyzed in a
flow cytometer 500 MPL system (Beckman Coulter).
Cell culture. Human Aortic Endothelial Cells (HAoECs) were maintained in
culture in endothelial cell growth medium MV2 (Promocell, Heidelberg,
Germany) supplemented with 1% streptomycin/penicillin (Lonza). Cells
were treated for 24 hours with ER stress inducer tunicamycin (0.8 µg/ml,
Sigma-Aldrich), 10 µg/ml of T lymphocyte MPs or those from non-
metabolic syndrome or metabolic syndrome subjects, in the absence or in
the presence of the ER stress inhibitor, TUDCA (100 µmol/l, Sigma-
Aldrich). In another set of experiments, 30 minutes before MP treatment,
cells were pre-treated with the NADPH oxidase inhibitor, apocynin (Apo,
100 µmol/l, Calbiochem, Darmstadt, Germany), the inhibitor of xanthine
oxidase, allopurinol (Allo, 50 µmol/l, Sigma-Aldrich), the inhibitor of
mitochondrial complexI NADH dehydrogenase, rotenone (Rot, 5 µmol/l,
Sigma-Aldrich), the NO. synthase inhibitor, L-NA (100 µmol/l, Sigma-
Aldrich), the mitochondria-targeted scavenger mito-TEMPO (25 nmol/l,
Santa Cruz Biotechnology) or the inhibitor of neutral SMase, GW4869 (10
µ PubMed mol/l, Sigma-Aldrich). All products were used at concentrations
at which no cytotoxicity was observed, as deduced from trypan blue
exclusion assay.
Western Blot. After treatment, cells were homogenized and lysed.
Proteins (40 µg) were separated on 4-12% NuPage gels (ThermoFisher
Scientific, Rockford, IL). Blots were probed with antibodies against PERK,
phospho-PERK, eIF2α, phospho-eIF2α, CHOP, phospho-Thr495 eNOS
(Cell Signaling, Danvers, MA), mitofusin 2 (Mfn2), VDAC1α (Abcam,
Cambridge, United Kingdom), p47-phox and phospho-Ser1177 eNOS (BD
Biosciences, San Jose, CA). A polyclonal mouse anti-human β-actin
antibody (Sigma-Aldrich) was used for standardization of protein gel
loading.
In another set of experiments, cells were pre-treated with LDL-R antibody
(5 µg/ml, R&D Systems, Minneapolis, MN) or its control IgG antibody for
30 minutes before MP treatment. Also, FasL carried by MPs was pre-
incubated with human anti-FasL (5 µg, BD Biosciences) for 30 minutes at
4°C to allow neutralization of MP FasL after being washed two times with
NaCl 0.9% in order to remove unbound anti-FasL antibody.
Nuclear translocation of ATF6 by confocal microscopy. Cells were seeded
on glass slides (Ibidi, Martinsried, Germany), for 24 hours and then
treated with either tunicamycin or MPs for 24 hours in the absence or
presence of TUDCA. Cells were then washed, and fixed with 4%
paraformaldehyde. Then, cells were tretaed with 5% bovine serum
albumin, permeabilized by 0.1% Triton, incubated with anti-ATF6 (Abcam)
for 1 hour, followed by 1 hour incubation with Alexa fluo-546 secondary
antibody (ThermoFisher Scientific) at room temperature. Finally, DAPI
(300 mmol/l, Santa Cruz Biotechnology) was added for 5 minutes. Cells
were washed and fluorescence was measured with a confocal microscopy
(CLMS 700, Zeiss, ZEN software). All images were acquired using x40
objective.
Quantitative and semi-quantitative PCR. Cells were treated for 6 hours as
described above and then, frozen cell pellets were used to investigate the
expression of mRNA for CHOP by RT-PCR (human forward primer
GAACGGCTCAAGCAGGAAAT, human reverse primer
TTCACCATTCGGTCAATCAGAG). Total RNA was isolated using miRNeasy
Qiagen microkit (Hilden, Germany). cDNA was generated using
PrimeScript TM RT reagent Kit (Takara/Clontech, Mountain View, CA) from
500 ng of RNA with random hexameric primers. RT-PCR analyses were
performed using a CFX96™ Real-Time PCR Detection System and SYBR
Green detection (Bio-Rad). Semi-quantitative PCR was made for the
expression of XBP-1 (human forward primer
AAACAGAGTAGCAGCTCAGACTGC, human reverse primer
TCCTTCTGGGTAGACCTCTGGGAG) by using PTC-200 (MJ Research, St
Bruno, Canada). β -Tubulin was used as the house keeping reference
gene.
siRNA transfection. Transient transfection of HAoECs was done according
to the manufacturer sʼ protocol (Santa Cruz Biotechnology). Briefly,
HAoECs were treated with either control siRNA or neutral SMAse siRNA
for 6 hours in a serum- and antibiotic-free medium. Cells were then
washed and normal fresh medium was added for 24 hours before
treatment with MPs for 24 hours.
NO. measurement. After treatment for 24 hours, as described above, cells
were loaded with 4, 5-diaminofluorescein diacetate (DAF-2DA, Santa Cruz
Biotechnology) (10 µmol/l) for 30 minutes at 37°C, and fluorescence was
measured.
Endothelial function. Aortic rings were obtained from male Swiss mice
bred at the animal facility at the University of Angers. After 24 hours of
MP incubation, aortic rings were mounted on a wire myograph filled with
physiological salt solution, as previously described (20). Endothelium-
dependent vasodilatation was studied by cumulative application of
acetylcholine (1 nmol/l-10 µmol/l, Sigma-Aldrich) in aortas with functional
endothelium precontracted with U46619 (Sigma-Aldrich).
Anion superoxide determination by EPR studies. The detection of anion
superoxide production was performed by EPR technique using 1-hydroxy-
3-methylcarbonyl-2, 2, 5, 5 tetramethyl pyrrolidine (CMH) (Noxygen,
Mainz, Germany) as spin trap. Briefly, after 24 hours of treatment, the
medium was replaced with 500 µl of deferoxamine-chelated Krebs-Hepes
solution containing CMH (500 µmol/l), deferoxamine (25 µmol/l, Sigma-
Aldrich), and sodium diethylthiocarmabate (5 µmol/l, Sigma-Aldrich), and
incubated for 45 minutes at 37°C. ROS measurement was performed on a
table-top x-band spectrometer Miniscope (MS200; Magnettech, Berlin,
Germany). Recordings were made at 77°K, using a Dewar flask.
Instrument settings were 10 mW of microwave power, 1 mT of amplitude
modulation, 100 kHz of modulation frequency, 150 seconds of sweep time
and three scans. The quantitative measurement of the O2.- signal
amplitude was reported to the relative units for protein concentration
(amplitude/µg/µl).
ROS measurement by dihydroethidium (DHE) or MitoSox staining.
Endothelial cells were grown on glass slides (Ibidi), and after different
treatments, they were washed and then incubated with either the
oxidative fluorescent dye DHE (5 µmol/l, Sigma-Aldrich) for 30 minutesat
37°C or MitoSox red (5 µmol/l, ThermoFisher Scientific) for 10 minutes at
37°C. Then, cells were fixed by 4% paraformaldehyde for 20 minutes at
room temperature. DAPI was added for 5 minutes. Finally, cells were
visualized with confocal microscopy (CLMS 700, Zeiss, ZEN software). All
images were acquired using an x63 objective.
Measurement of whole cell respiration. Respiration rates were measured
in treated HAoECs. The cells were collected by trypsinization, washed
once in culture medium and centrifuged (500g, 5 minutes). The pellet was
resuspended in respiratory medium, corresponding to normal culture
medium without FBS and antibiotics, both reagents known to interfere
with mitochondrial respiration. Mitochondrial oxygen consumption was
measured at 37°C using a high-resolution Oxygraph-2K respirometer
(Oroboros, Innsbruck, Austria). Oxygraphy experiments were performed
on cells cultured in T75 flasks, corresponding to an average of 5x106 cells
per flask. Basal respiration rate of cells was determined by measuring the
linear rate of oxygen consumption. Oligomycin (1 µg/ml) was then added
to determine the non-phosphorylating respiration rate. The uncoupling
respiration rate was also recorded by stepwise addition of FCCP (0.2-1
µmol/l) up to the optimal concentration representing the maximal capacity
of the respiratory chain without the regulation of ATP synthase. Finally, the
non-mitochondrial oxygen consumption rate was determined by adding
antimycin A (1 µg/ml). At the end of the experiment, a standard volume of
respiratory medium is collected and centrifuged for 2 minutes at 16,000g.
The cell pellet was then resuspended in NaCl (0.9%) and protein
concentration was determined spectrophotometrically. Respiration rates
were expressed in nmoles of O2 consumed per minute and per mg
protein.
Mitochondrial enzyme activity measurements. The activity of the different
mitochondrial respiratory chain complexes was measured on cell
homogenates, at 37°C, using a SAFAS spectrophotometer (SAFAS,
Monaco, France).
Statistics. Data are expressed as mean±SEM. Statistical analyses were
performed by a one-way ANOVA and then Mann-Whitney U, or ANOVA for
repeated measures and subsequent Bonferroni post hoc test. P<0.05 was
considered to be statistically significant.
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Figure 1: T lymphocytic microparticles (MPs) induce endoplasmic
reticulum (ER) stress response. Effects of MPs on the three canonical
arms of ER stress response. TUDCA was used to inhibit ER stress
response. (A-C) Anti-phospho-PERK, anti-phospho-eIF2α, anti-CHOP
and anti-β actin antibody immunoblots of human aortic endothelial cells.
(D) Semiquantitative PCR of XBP-1. (E) Immunofluorescent staining
showing the nuclear translocation of ATF6. (F) Nitric oxide (NO.)
production measured by electronic paramagnetic resonance. (G)
Endothelial-dependent vasorelaxation induced by acetylcholine (Ach) on
mouse aortic rings. *P<0.05, **P<0.01. For statistical analyses, one-way
analysis of variance and Mann-Whitney U or analysis of variance for
repeated measures and subsequent Bonferroni post hoc test for
acetylcholine-induced vasorelaxation were used. n=3-4.
Figure 2: ER stress response induced by T lymphocytic
microparticles (MPs) is mediated by neutral sphingomyelinase
(SMase) activation via Fas/Fas-Ligand interaction and LDL-receptor.
(A-C) Effects of MPs on ER stress response (phospho-eIF2α) and Smase
expression are inhibited by anti-Fas-Ligand or LDL-receptor antibodies.
(D-H) Pharmacological inhibition of SMase with GW4869 or silencing with
siRNA abolished MP-induced ER stress response and endothelial
dysfunction.*P<0.05. For statistical analyses, one-way analysis of variance
and Mann-Whitney U were used. n=3-4.
Figure 3: Cytosolic production of reactive oxygen species by MPs is
upstream of ER stress response. (A, B) Effects of 24 hours treatment
with inhibitors of ROS sources on ER stress response (phospho-eIF2α) in
the absence (A) or in the presence of MPs (B). (C-I) Cytosolic ROS
production measured by electronic paramagnetic resonance (C-E) and
DHE labeling (F-I). (J) Effects of inhibitors of ROS sources on ROS
production after 4 hours of MP treatment. (K) Effects of silencing SMase
on MP-induced p47phox expression. *P<0.05, **P<0.01, ***P<0.001. For
statistical analyses, one-way analysis of variance and Mann-Whitney U
were used. n=3-7.
Figure 4: Mitochondrial production of reactive oxygen species by
MPs is downstream of ER stress response. (A-D) Mitochondrial ROS
production measured by MitoSox labelling. (E) Scavenging mitochondrial
ROS with Mito-Tempo has not effect on ER stress response. (F-I) Effects
of MPs on mitochondrial respiration and complex IV activity. (J and K)
Effects of MPs on mitochondria-associated membranes. (L) Mito-Tempo
improves NO. production induced by MPs. *P<0.05, **P<0.01. For
statistical analyses, one-way analysis of variance and Mann-Whitney U
were used. n=4-6.
Figure 5: Microparticles from metabolic syndrome patients (MetS
MPs) induce endoplasmic reticulum (ER) stress response via Fas/Fas-
Ligand interaction and neutral sphingomyelinase (SMase) pathway.
Effects of MPs from non-metabolic syndrome subjects (nMetS MPs) and
MetS MPs on the canonical arms of ER stress response. TUDCA was used
to inhibit ER stress response. (A) Anti-phospho-eIF2α antibody
immunoblots of human aortic endothelial cells. (B) Immunofluorescent
staining showing the nuclear translocation of ATF6. (C) Nitric oxide (NO.)
production measured by electronic paramagnetic resonance.
(D)Endothelial-dependent vasorelaxation induced by acetylcholine (Ach)
on mouse aortic rings. (E and F) Effects of MPs on ER stress response
(phospho-eIF2α) and SMase expression are inhibited by anti-Fas-Ligand
antibodies. (G and H) Silencing SMase with siRNA abolished MP-induced
ER stress response. *P<0.05, **P<0.01. For statistical analyses, one-way
analysis of variance and Mann-Whitney U or analysis of variance for
repeated measures and subsequent Bonferroni post hoc test for
acetylcholine-induced vasorelaxation were used. n=3-4.
Figure 6: Cytosolic and mitochondrial production of reactive oxygen
species (ROS) by MetS MPs are downstream of ER stress response.
(A-D) Cytosolic ROS production measured by DHE staining. (E-H)
Mitochondrial ROS production measured by MitoSox labelling. For
statistical analyses, one-way analysis of variance and Mann-Whitney U
were used. n=4.
Figure 7: neutral sphingomyelinase controls p47phos expression.
siRNA against neutral sphingomyelinase (SMAse) prevents on p47phox
expression induced by MetS MPs at 4 hours (A), but not at 24 hours (B).
*P<0.05. For statistical analyses, one-way analysis of variance and Mann-
Whitney U were used. n=4.
Figure 8: Schematic overview of effects of T lymphocytic
microparticles (MPs) (A) and MPs from metabolic syndrome patients
(MetS MPs) (B) on endothelial cells. (A) MPs from apoptotic T cells act
on Fas and LDL-receptors, then, via neutral SMase cascade induce
cytosolic ROS production which activates ER stress. Through the
interaction between ER and mitochondria, mitochondrial ROS are
increased and contribute to decreased bioavailability of NO. and the
subsequent impairment of endothelium-dependent vasorelaxation. (B)
Fas/FasL, but not LDL-receptor, participates in the response induced by
MetS MPs. In addition, neutral SMase activation induces directly ER stress
which, in turn, increases both cytosolic and mitochondrial ROS. All of
these events lead to reduction of NO. release and the subsequent
impairment of endothelium-dependent vasorelaxation.
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